 A number of monoclonal antibodies that bind to and inhibit PCSK9 near the catalytic domain were in clinical trials .These include evolocumab (Amgen), bococizumab (Pfizer), and alirocumab (Sanofi/Regeneron Pharmaceuticals)., the EU approved these drugs including Evolocumab/Amgen according to Medscape news agency report.